Without precedent for over two decades, a treatment has been appeared to enhance to what extent patients with cutting edge little ...
Read More
Home / Archive for 10/20/18
IMMUNOTHERAPY DRUG CEMIPLIMAB HAS BEEN LICENSED FOR ADVANCED SQUAMOUS CELL SKIN CANCER
The Food and Drug Administration (FDA) has affirmed the medication cemiplimab (Libtayo) for patients with a propelled type of ...
Read More
Subscribe to:
Posts
(
Atom
)